Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Preoperative chemotherapy improves outcomes for pediatric sarcomas like Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma.
• Adult soft tissue sarcoma (STS) patients with tumors >10 cm face high risks of distant recurrence and death.
• Current use of adjuvant/neoadjuvant chemotherapy in adult STS is inconsistent.

Purpose of the Study:

• To evaluate the potential role of neoadjuvant chemotherapy in adult soft tissue sarcoma.
• To explore the use of investigational therapies in high-risk STS patients.
• To address the lack of consensus regarding chemotherapy indications in STS.

Main Methods:

• Review of existing literature on neoadjuvant and adjuvant chemotherapy in adult soft tissue sarcoma.
• Analysis of risk factors for recurrence and mortality in STS.
• Discussion of treatment strategies for large STS tumors.

Main Results:

• Adult STS patients with tumors >10 cm are candidates for neoadjuvant chemotherapy.
• Chemotherapy offers potential benefits but carries substantial toxicity risks.
• There is significant variation in the application of chemotherapy for STS.

Conclusions:

• Neoadjuvant chemotherapy should be considered for high-risk adult soft tissue sarcoma patients.
• Further research is required to establish evidence-based guidelines for chemotherapy use in STS.
• Balancing treatment benefits against chemotherapy toxicity remains a clinical challenge.